Aslan Pharmaceuticals   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Singapore Singapore (2010)

Organization Overview

First Clinical Trial
2012
NCT01614522
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Aslan Pharmaceuticals | ASLAN Pharmaceuticals Pte Ltd | contact@aslanpharma.com

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Biliary Tract Neoplasms (Phase 2)

Cholangiocarcinoma (Phase 2)

Dermatitis (Phase 1)

Dermatitis, Atopic (Phase 1)

Eczema (Phase 1)

Hypersensitivity (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Neoplasms (Phase 2)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial APIs: 11